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Abstract
Introduction: Curcuminoids may improve pathological conditions associated with Alzheimer’s disease. However,
their therapeutic potential is limited by their exceedingly low bioavailability after oral administration. A method to
deliver solubilized curcuminoids by injection was evaluated in Alzheimer transgenic mice.
Methods: Amyloid protein precursor (APP)SWE, PS1dE9 mice were intravenously or subcutaneously injected at
weekly intervals between the ages of 4 and 12 months with serum- or cyclodextrin-solubilized curcuminoids to
assess their potential for plaque prevention. Alternatively, mice between the ages of 11 and 12 months were
intravenously injected with cyclodextrin-solubilized curcuminoids at biweekly intervals to evaluate their ability to
eliminate existing plaques. Plasma and brain levels of curcuminoids and their metabolites were also determined
after subcutaneous and intravenous injection.
Results: Weekly long-term injections did not result in a significant plaque load reduction. However, intravenous
injection of cyclodextrin-solubilized curcuminoids at higher curcuminoid concentrations and at a biweekly
frequency between the ages of 11 and 12 months reduced the plaque load to approximately 70% of the control
value. After intravenous injection, plasma levels of 100 μM curcuminoids and brain levels of 47 nmol/g could
initially be achieved that declined to essentially undetectable levels within 20 minutes. The primary curcuminoid
metabolites in plasma were the conjugates of glucuronide or sulfate and hexahydrocurcuminoids as reduction
products. In the brain, both hexahydrocurcuminoids and octahydrocurcuminoids were detected as major
metabolites. After subcutaneous injection, maximal curcuminoid plasma levels of 23 μM and brain levels of 8
nmol/g were observed at 30 minutes after injection and curcuminoids remained detectable for 2 to 3 h.
Conclusion: Curcuminoids are rapidly metabolized after injection and their effect on reducing plaque load
associated with Alzheimer’s disease may be dependent on the frequency of administration.
Introduction
Curcumin is a yellow pigment extracted from the spice
and coloring agent turmeric, where it occurs in amounts
of 2 to 8% [1]. Commercial curcumin preparations
typically contain a mixture of polyphenols, collectively
referred to as curcuminoids. In addition to the primary
component curcumin (CUR, 65 to 80%), they also
contain smaller amounts of the co-extracted congeners
demethoxycurcumin (DMC, 15 to 25%) and bisde-
methoxycurcumin (BDMC, 5 to 15%) [2-4].
Curcumin binds to Ab fibrils, presumably in the enol
form [5], and stains amyloid plaques and neurofibrillary
tangles in brain sections [6,7] and in vivo [8-10]. Curcu-
min inhibits Ab fibril formation and promotes disaggre-
gation of existing fibrils in vitro with IC50 values of 0.19
to 1 μM [9,11,12], although much higher IC50 values in
the 10 to 12 μM range have been reported [13,14]. Cur-
cumin similarly inhibits plaque formation or disrupts
* Correspondence: wolfgang.quitschke@stonybrook.edu
1Department of Psychiatry and Behavioral Science, Stony Brook University
Medical Center, 100 Nicolls Road, Stony Brook, New York 11794-8101, USA
Full list of author information is available at the end of the article
Quitschke et al. Alzheimer’s Research & Therapy 2013, 5:16
http://alzres.com/content/5/2/16
© 2013 Quitschke et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
existing plaques in Alzheimer transgenic mouse models
either after oral uptake [9,15-17] or intravenous (i.v.)
injection [8]. Apart from the direct interaction with Ab
fibrils, curcuminoids may reduce plaque formation or
ameliorate their effects by increasing Ab uptake by
macrophages [18], affecting amyloid protein precursor
(APP) maturation [19], modulating APP processing
enzymes [20,21], protecting neurons from Ab induced
toxicity [9,22-24] or influencing the expression of genes
associated with apoptosis and inflammation [25]. Alter-
natively, curcumin degradation products may mediate
similar effects (Review: [26]).
Despite such promising observations, the clinical use
of orally administered curcuminoids is severely limited
by their exceedingly low bioavailability, which is a direct
consequence of their poor solubility in aqueous solu-
tions and their rapid metabolic conversion (Reviews:
[26-28]). To improve systemic availability, formulations
containing high concentrations of curcuminoids were
solubilized in either serum [29] or 2-hydroxypropyl-g-
cyclodextrin (HP-g-CD) and injected into Alzheimer
transgenic mice. The effect on plaque development,
systemic availability and metabolism was investigated.
Materials and methods
Curcuminoid solubilization
Technical grade curcumin (Cayman Chemical Company,
Ann Arbor, MI, USA) containing CUR (69%), DMC
(19%) and BDMC (12%) was solubilized in either
C57BL/6 mouse serum (Valley Biomedical, Winchester,
VA, USA) or in an aqueous solution of 10% HP-g-CD
(Sigma-Aldrich, St. Louis, MO, USA) containing 0.6%
NaCl, pH 6.8 by the sequential mixing with solid- and
DMSO-dissolved curcumin as described elsewhere [29].
Briefly, 50 ml of serum or 10% HP-g-CD was mixed by
stirring with solid curcuminoids (50 mg/ml) for 16 h at
4°C. Thereafter, the suspension was clarified by centrifu-
gation at 18,000 × g for 30 minutes. The supernatant
was removed and DMSO-dissolved curcuminoids at a 1
M concentration were added (10 μl/ml) and again stir-
red for 16 h. The resulting suspension was then clarified
by two successive centrifugations at 18,000 × g. The
supernatant was sterilized by filtration through a 0.45
μm membrane filter (Pall Corporation, Ann Arbor, MI,
USA). The final supernatants contained either 3-4 mM
total curcuminoids solubilized in serum or 24 mM cur-
cuminoids solubilized in 10% HP-g-CD (full-strength).
Animals, injections and tissue preparation
For the study on plaque prevention, female APPSWE,
PS1dE9 transgenic mice (Jackson Laboratories, Bar Har-
bor, ME, USA) were i.v. injected with serum-solubilized
curcumin via the tail vein once per week starting at four
months of age. The average weight of the mice was
about 25 g (range: 23 to 27 g) and they were injected
with a total volume of 0.1 ml serum-solubilized curcu-
minoids. This protocol was discontinued after five injec-
tions (four weeks) due to adverse reactions. As an
alternative, full-strength HP-g-CD-solubilized curcumi-
noids were diluted four-fold with isotonic saline to a
concentration of 6 mM and similarly injected until the
mice had reached the age of about 10.5 months. For the
remaining six weeks, the mice were subcutaneously (s.c.)
injected between the shoulder blades at weekly intervals
with 0.4 ml full-strength HP-g-CD-solubilized curcumi-
noids until the final age of 12 months. For the study on
plaque resolution, mice at 11 months of age were i.v.
injected for 1 month twice weekly (nine injections) with
0.1 ml of full-strength HP-g-CD-solubilized curcumi-
noids. The brains from a total of 23 mice were success-
fully processed for histological evaluation. These
included one negative control without transgenes, three
positive controls without injections, three positive con-
trols each with injections for plaque prevention and
plaque resolution, six experimental mice injected for
plaque prevention and seven mice for plaque resolution.
Brain and plasma levels following curcuminoid injec-
tion were analyzed in wild type C57BL/CH3, transgenic
C57BL/CH3 and CV-1 mice. Since the CV-1 mice were
larger with an average weight of about 50 g (range: 45 to
55 g), these were i.v injected with 0.2 ml or s.c. injected
with 0.8 ml of full-strength HP-g-CD-solubilized curcu-
minoids to account for the larger mass and blood
volume. After injection, mice were sacrificed by exposure
to CO2 at selected time intervals. Blood (approximately 1
ml) was collected by cardiac puncture into tubes contain-
ing EDTA and the tissues were subsequently removed
and stored at -75°C until further processing. The blood
was centrifuged at 14,000 × g for one minute for plasma
collection.
To estimate the maximum uptake/binding of curcumi-
noids in the brain under the applied i.v. injection condi-
tions, one CV-1 mouse was exposed to curcuminoids by
cardiac perfusion, as modified from the procedure
described below. The mouse was sequentially perfused
with 10 ml mouse serum, 30 ml mouse serum contain-
ing 5% full-strength HP-g-CD-solubilized curcuminoids,
and then washed with 30 ml of PBS.
All procedures involving animal handling and proces-
sing were approved by the Stony Brook University Insti-
tutional Animal Care and Use Committee (IACUC) in
compliance with the National Institutes of Health
guidelines.
Amyloid plaque staining of brain sections and
quantitative analysis
At the age of 12 months, all mice were prepared for his-
tological evaluation. Terminal deep anesthesia was
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induced by s.c. injection of 0.2 ml of pentobarbital
(50 mg/ml). The chest cavity was exposed and a blunt
syringe needle inserted into the left ventricle of the
heart. The right atrium was cut open and the mice were
sequentially perfused with 10 ml of wash solution
(NaCl, 8 g/L; dextrose, 4 g/L; anhydrous CaCl2, 0.23 g/
L; sodium cacodylate trihydrate, 0.34 g/L) and 30 ml of
fix solution (sucrose, 40 g/L; paraformaldehyde, 40 g/L;
sodium cacodylate, 14.34 g/L; pH 7.2). The whole heads
stripped of skin and eyes were placed in 30 ml of
sodium cacodylate buffer (0.2 M, pH 7.4) and shipped
to NeuroScience Associates (Knoxville, TN, USA) for
further processing.
Brains were removed from skulls and treated with 20%
glycerol and 2% dimethylsulfoxide to prevent freeze-
artifacts, and embedded in a gelatin matrix using Multi-
Brain Technology® (NeuroScience Associates). After
curing, the block of embedded brains was rapidly frozen
by immersion in isopentane chilled to -70°C with crushed
dry ice, and mounted on a freezing stage of an AO 860
sliding microtome. The MultiBrain® block was sectioned
coronally at 35 μm. Sections were sequentially collected
into 24 containers that were filled with Antigen Preserve
solution (49% PBS pH 7.0, 50% ethylene glycol, 1% poly-
vinyl pyrrolidone). At the completion of sectioning, each
container held a serial set of 1-of-every-24th section (one
section every 840 μm). Each of the MultiBrain® sections
cut from the block was a composite holding individual
sections from each of the brains embedded in the block.
With such composite sections, uniformity of staining was
achieved across treatment groups.
Brain sections were silver-stained according to the
Campbell-Switzer Alzheimer’s method for plaques and
tangles [30,31]. Overall, this stain displays sensitivity and
specificity properties comparable to immunohistoche-
mical methods [32-35]. MultiBrain® sections were
collected and stained free-floating at room temperature.
The sections were placed in freshly prepared 2% ammo-
nium hydroxide for five minutes, and then transferred
sequentially to a silver-pyridine-carbonate solution for
40 minutes, 1% citric acid for 3 minutes and 0.5% acetic
acid until ready for development. The sections were
developed in Physical Developer ABC solution (after
Gallyas; containing sodium carbonate, citric acid, tung-
stosilicic acid and formaldehyde) with the development
time being visually assessed. The development was
stopped by placing the sections briefly in 0.5% acetic
acid. Sections were mounted on gelatinized (subbed)
glass slides, dehydrated and cover-slipped.
The Alzheimer’s disease (AD) plaque burden was deter-
mined by quantifying and averaging the plaque area per-
centage of cortical area from four sections per animal. The
coronal section containing the full anterior commissure
was chosen as the first section to quantify, and the
subsequent three stained sections completed the set of
four. Individual slides containing an entire MultiBrain®
section were scanned at 4X as high-resolution 24 bit color
tif files. The color density of the images was adjusted in
Photoshop® to provide contrast between the plaques and
the background, but without using Brightness-Contrast as
this function changes the size of the plaques. The thresh-
old of each image was determined to provide an image
with plaques and no background in ImageJ (NIH,
Bethesda, MD, USA). Using the threshold adjustment, a
level was determined that removed the background while
leaving plaques intact. Plaque size and number was quan-
tified in ImageJ with Size = 0 to infinity and circularity = 0
to 1. From Analyze > Particles, the result was copied into
a spreadsheet for the appropriate level of the image (1 to
4). This process was repeated for all images. Percent pla-
que area was calculated in Excel® and graphed in Sigma-
Plot™ (11.2) according to animal number and plaque
density.
Tissue and plasma extraction for reversed phase
chromatography
Approximately 200 mg of brain tissue (approximately
one hemisphere) was homogenized in 0.7 ml of 50%
acetonitrile, 0.01% ammonium acetate, pH 4.5 (total
volume approximately 0.9 ml). The homogenate was
transferred to a 1.5 ml microcentrifuge tube and centri-
fuged for five minutes at 18,000 × g. Subsequently, 0.4
ml of the supernatant was removed and transferred to a
fresh microcentrifuge tube, which was then mixed with
0.8 ml of acetone and left for 12 to 16 h at -20°C. The
precipitated protein was centrifuged at 14,000 × g for
five minutes and the clear supernatant was transferred
to a fresh tube and evaporated under vacuum. The dry
residue was re-solubilized in 0.2 ml 37.5% acetonitrile,
0.01% ammonium acetate, pH 4.5 and clarified by cen-
trifugation and the supernatant was loaded onto a
reversed phase column and separated as described else-
where [29,36]. Plasma (0.2 ml) was mixed with an equal
volume of 50% acetonitrile, acetone precipitated and
then processed the same way as the brain tissue.
Analysis of curcuminoids and metabolites
Curcuminoids and their conjugated metabolites were sepa-
rated by reversed phase chromatography and monitored at
an absorption wavelength of 427 nm. Curcuminoids were
quantitated based on standard curves for curcumin (analy-
tical grade) by integration of the peaks with the FPLC
Unicorn™ (version 5.10) program (GE Healthcare Life
Sciences, Piscataway, NJ, USA). The molar absorptivities
(ε) of the three curcuminoids dissolved in ethanol were
shown to range from 6.73 (x 104 L cm-1mol-1) for
CUR, 5.78 for DMC and 4.95 for BDMC at 425 nm [37].
Since the molar absorptivity for curcumin dissolved in
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acetonitrile was essentially the same as in ethanol, the inte-
grated values of the DMC and BDMC peaks were multi-
plied by the respective factors 1.17 and 1.36 to obtain
molar concentrations in all experiments. The conjugated
metabolites were identified by mass spectrometry as
described elsewhere [36] and they were assumed to have
the same molar absorption as their parental counterparts
[38]. The reductive metabolites of curcuminoids were
visualized at an absorption wavelength of 280 nm or 310
nm. The molar absorptivities of the hexa- and octahydro-
curcuminoids were taken from the data presented by
Hoehle et al. [39], which were in excellent agreement with
standard curves generated with commercial preparations of
hexahydrocurcumin (Sigma-Aldrich) and octahydrocurcu-
min (Sabinsa Corporation, East Windsor, NJ, USA). Unless
otherwise indicated, all data points were calculated as the
average of 3 to 10 independent experiments. Error bars
represent the standard deviation from the mean.
Curcuminoid binding to NT2/D1 cells
NT2/D1 cells were grown in 25 cm2 flasks to a density of
about 90% confluence (6 to 8 × 106 cells) with 6 ml of
Dulbecco’s Minimal Essential Medium (DMEM) contain-
ing 5% fetal calf serum (FCS). For curcuminoid dose
curves to determine binding dissociation constants,
media were prepared with increasing amounts (10 μl to 2
ml) of curcuminoids solubilized in mouse serum or 10%
HP-g-CD and supplemented with DMEM for a total
volume of 6 ml. Media for serum competition curves
were prepared by adding 300 μl of solubilized curcumi-
noids to a total volume of 6 ml. The remaining volume
consisted of varying ratios of DMEM and mouse serum
to generate dose curves with constant curcuminoid and
variable serum concentrations. Curcuminoids solubilized
in mouse serum at a 4 mM initial concentration yielded a
final media concentration of 200 μM. Curcuminoids
solubilized in HP-g-CD were either used full-strength
(24 mM) or diluted with 0.6% saline to a 6 mM concen-
tration, resulting in final media concentrations of
1.2 mM and 300 μM, respectively. After 1 h incubation,
0.4 ml of medium was withdrawn for the determination
of free curcuminoids and mixed with 0.8 ml of acetone.
Cells were then washed three times in the flasks with
5 mL of 0.9% saline and then scraped into 1 ml of the
same solution. The cell suspension was centrifuged at
3,000 × g for one minute and the supernatant removed.
The cell pellet was resuspended in 1 ml of 0.6% saline
and re-centrifuged. The final pellet was suspended in
0.4 ml of 0.6% saline and mixed with 0.8 ml of acetone.
All samples were stored at -20°C for 2 to 16 h and
processed for reversed phase chromatography as
described above for tissue preparation. After curcumi-
noid quantitation, data points were combined from three
independent experiments, normalized to 106 cells, and
fitted to a ligand binding function (y = (BMAX*x)/(KD+x)
+NSx) or a hyperbolic decay function (y = ab/(b+x))
using SigmaPlot™(11.2) as described elsewhere [36].
Results
Curcuminoids solubilized in serum and HP-g-CD
To assess the use of solubilized curcuminoids as a thera-
peutic or preventative agent in the treatment of Alzhei-
mer’s disease, technical grade curcumin was initially
solubilized in mouse serum. Technical grade curcumin
is the type of preparation used in the vast majority of
studies on this compound and it contains all three cur-
cuminoids as they are represented in the turmeric pow-
der. All three curcuminoids were included in this study
to neutralize any effects due to their differential chemi-
cal stability, metabolic conversion or cellular binding
affinity [29,36]. Furthermore, all three curcuminoids
have been shown to inhibit Ab fibrillogenesis and they
may complement each other to inhibit the process that
leads to plaque formation [40]. The sequential solubili-
zation of solid and DMSO-dissolved curcumin yielded a
total soluble concentration of 3-4 mM and a curcumi-
noid distribution as depicted in Figure 1A. The feasibil-
ity of using such serum-solubilized curcuminoids for i.v.
injection was initially tested on Sprague-Dawley rats
using serum derived from random animals of the same
strain. Rats were injected weekly via the tail vein with
serum-solubilized curcuminoids at approximately 7% of
the total blood volume for up to four months without
adverse effects.
A similar injection protocol was adapted for the Alz-
heimer transgenic mouse strain APPSWE, PS1dE9, which
is a hybrid from a cross between C57BL/6 and C3H mice
[41]. Since serum from such a cross is commercially
unavailable, serum derived from C57BL/6 mice was used.
The first two injections proceeded uneventfully. How-
ever, after the third injection adverse reactions occurred
that were consistent with anaphylaxis. Since such reac-
tions were also observed in control mice injected with
serum devoid of curcuminoids, it was concluded that
these were caused by incompatible serum components.
Most mice recovered within one hour; however, some
fatalities occurred. It was, therefore, deemed impossible
to continue with such serum injections and a new vehi-
cle for the solubilization of injectable curcumin had to
be found.
Solubilizing curcuminoids in 10% HP-g-CD proved to
be ideal for this purpose. Mixing either solid curcumi-
noids or DMSO-dissolved curcuminoids with 10% HP-g-
CD, preferentially solubilized BDMC or CUR, respec-
tively. As such, the distribution of individual curcumi-
noids followed the same pattern as that observed with
serum or albumin solutions [29]. To maximize the
amount of curcuminoids solubilized and to limit the
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final concentration of DMSO to 1%, curcuminoids were
added sequentially, first as a solid powder followed by
DMSO-dissolved curcuminoids. This resulted in a cur-
cuminoid distribution that was very similar to that
obtained with serum by the same procedure (Figure
1A), albeit with a higher final curcuminoid concentra-
tion of approximately 24 mM. Upon diluting such cur-
cuminoid solutions with serum, no precipitation
occurred that might have had adverse effects on the cir-
culation. In addition, the HP-g-CD solubilized curcumi-
noids partially equilibrated with serum components as
evidenced by a shift in color from yellow to deep red,
which is similar to the color of curcuminoids directly
solubilized in serum (Figure 1B). For long-term i.v.
injection studies, the full-strength HP-g-CD-solubilized
curcuminoids were diluted four-fold to a final concen-
tration of 6 mM curcuminoids in 2.5% HP-g-CD. This
resulted in a curcuminoid concentration similar to that
obtained by serum-solubilization, which caused no
adverse effects. In addition, the amount of HP-g-CD
(100 mg/kg) injected was below that considered toxic
for chronic exposure [42].
The effect of injecting soluble curcuminoids on plaques
in Alzheimer transgenic mice
The transgenic mouse line APPSWE, PS1dE9 contains the
Swedish mutations (K595N/M596L) within a chimeric
mouse/human APP695, and the human transgene for
presenilin 1 with a deletion of exon 9 [41]. This mouse
line begins to develop plaques at 4 to 6 months of age,
which progresses to extensive plaque load by 12 months
of age [43]. The ability of curcuminoids to prevent amy-
loid plaque formation was studied by weekly tail vein
injections. Injections of 0.1 ml serum-solubilized curcu-
minoids (4 mM) were started at the age of four months
and replaced with HP-g-CD-solubilized curcuminoids
(6 mM) four weeks later. At the age of about 10.5
months, the tail veins of many mice had deteriorated to
the point that further i.v. injections were rendered impos-
sible. For the last six weeks, until the age of 12 months,
tail vein injections were, therefore, replaced with weekly
s.c. injections of 0.4 ml full-strength (24 mM) HP-g-CD-
solubilized curcuminoids. The ability of curcuminoids to
resolve existing plaques was investigated by tail vein
injection twice weekly with 0.1 ml of 24 mM HP-g-CD-
solubilized curcuminoids. Nine injections were carried
out between the ages of 11 and 12 months (Figure 2A).
The i.v. injection of 6 mM HP-g-CD-solubilized cur-
cuminoids caused no obvious detrimental effects. How-
ever, within seconds after i.v. injection of curcuminoids
at 24 mM concentrations, acute reactions were observed
that included trembling and agitation followed by a per-
iod of lethargy. These reactions subsided within five
minutes after injection and caused no deaths in other-
wise healthy animals. Such effects were not observed in
control animals and it was concluded that curcuminoids
were toxic at these high concentrations. The rapid reso-
lution of symptoms is consistent with the notion that
curcuminoids are rapidly metabolized. No adverse
effects were noted after s.c. injections.
At the age of 12 months, transgenic mice showed
vigorous amyloid plaque development compared to a
negative control not carrying the transgene (Figure 2B,
C). The plaque load in the experimental groups was
determined for plaque prevention (N = 6) and for pla-
que resolution (N = 7). Included were also positive con-
trol mice that had not received any injections (N = 3),
and mice from each group (N = 3) that had received
injections of the solubilization vehicle without curcumi-
noids. The average plaque loads between the three
control groups showed no significant differences. For
statistical purposes, the three control groups were,
therefore, combined (N = 9) and compared with the
Figure 1 Curcuminoid solubilization. (A) Chromatograms of
curcuminoids solubilized either in serum (left panel) or 10% HP-g-
CD (right panel). The relative contribution of each curcuminoid (%)
relative to the total amount (100%) is indicated. (B) The color of
curcuminoids solublized in 10% HP-g-CD (1) compared to normal
serum (2), curcuminoids solubilized directly in serum (3), and HP-g-
CD-solubililized curcuminoids diluted to 5% with serum (4).
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Figure 2 Amyloid plaques in brains of mice and the effect of curcuminoid injections. (A) Time course of curcuminoid injections into
Alzheimer transgenic mice. Arrowhead denotes the time point when serum-solubilized curcuminoids were switched to HP-g-CD-solubilized
curcuminoids, asterisk when i.v. injections were replaced with s.c. injections. (B) Silver stained brain section from a control non-transgenic mouse
without plaques. (C) Comparable section from an Alzheimer transgenic mouse at the age of 12 months. (D) The effect of curcuminoid injections
on amyloid plaque load. Left panel: Alzheimer transgenic control mice were analyzed at 12 months of age and received either no injections
(n = 3), or injection of vehicle alone according to the protocols for plaque prevention (n = 3) or plaque resolution (n = 3). The differences in the
relative plaque levels in each of the groups were not statistically different and the values were combined and assigned the value of 100%
(n = 9). Right panel: The combined control group was compared to experimental mice that had been injected for plaque prevention (n = 6)
or plaque resolution (n = 7) with a statistical difference defined at the level of P < 0.05 (*P = 0.0496).
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experimental groups (Figure 2D). The plaque load of
mice that had received weekly injections of curcumi-
noids for eight months for plaque prevention, showed
no significant difference from the control group,
although the overall average was slightly reduced. Mice
that received bi-weekly injections of curcuminoids at a
four-fold higher concentration for four weeks for plaque
resolution, had a statistically significant (P < 0.05) lower
plaque load at approximately 70% of the control value
(Figure 2D).
These results demonstrate that sporadic injections of
curcuminoids did not result in the panacea initially
hoped for. To design more effective injection protocols
with the goal of achieving a more robust response, the
fate of curcuminoids after both i.v. and s.c. injections
was further examined.
Curcuminoid levels in plasma and brain after intravenous
and subcutaneous injection
After i.v. injection, curcuminoids and selected metabo-
lites were measured in plasma and brain (Figure 3) from
both wild type and transgenic C57BL/CH3, as well as
CV-1 mice. Since the data from both strains of mice were
indistinguishable beyond what would be attributable to
individual variations, the results were combined for
statistical purposes. Unmodified curcuminoids and their
sulfate and glucuronide conjugates were detected in
plasma at a 427 nm absorption wavelength (Figure 3A).
The hexa- and octahydrocurcuminoid reduction products
were detected in both plasma and brain at the 280 nm
wavelength (Figure 3B). Significant amounts of di- and
tetrahydrocurcuminoids were not observed. In addition,
conjugates of reduction products or diconjugate curcu-
minoids could not be reliably determined, either because
their concentration was too low or their absorption peaks
overlapped with those from numerous co-extracted unre-
lated compounds that eluted close to the front.
Initial plasma concentration of curcuminoids reached
a high level of approximately 100 μM immediately fol-
lowing i.v. injection (Figure 4A), which declined rapidly
to essentially undetectable levels within 20 minutes.
Both conjugation and reduction products were also
transiently observed in plasma at concentrations below
20 μM (Figure 4A, B). Curcuminoid sulfates and glucur-
onides in plasma occurred concurrently in individual
mice, but their relative levels varied widely between
animals and time after injection. Overall, the level of
sulfates peaked early and declined to low levels by 15
minutes while glucuronides persisted longer and were
detected for up to 1 h. The primary reduction products
in plasma were hexahydrocurcuminoids and these per-
sisted for at least 30 minutes. Octahydrocurcuminoids
were detected transiently at low levels between 20 and
30 minutes after injection (Figure 4B).
After s.c. injection, peak plasma curcuminoid levels
were delayed compared to i.v. injection and they gradu-
ally reached a maximum after 30 minutes at 23 μM.
Lower levels of curcuminoids (approximately 1 μM)
could be detected for up to 4 h. The peak level of cur-
cuminoid conjugates occurred with a delay compared to
the parental compounds at 1 h after s.c. injection
(Figure 5A). The primary monoconjugates were consis-
tently glucuronides, which at peak levels were about
five-fold higher than sulfates (Figure 5B). Significant
amounts of reduction products were not observed after
s.c. injection.
In brain tissue, the highest levels of curcuminoids
(approximately 47 nmol/g) occurred with a slight delay
compared to plasma at two minutes after i.v. injection.
No curcuminoid conjugates were observed, which indi-
cated that contamination with blood was insignificant.
Figure 3 Elution profiles of curcuminoids and metabolites in
mice after i.v. injections. (A) Chromatogram (427 nm) of
curcuminoids and monoconjugates of sulfate and glucuronide
extracted from plasma five minutes after injection. (B)
Chromatogram (280 nm) of octahydro- and hexahydrocurcuminoids
extracted from brain 15 minutes after injection.
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Figure 4 Concentration of curcuminoids and metabolites in plasma (uM) and brain (nmol/g) after i.v. injection. (A) Time course of total
curcuminoids (◊), reduction products (hexa- + octacurcuminoids, ▼), and monoconjugates (sulfates + glucuronides, ▲) in plasma. (B) Time
course of individual metabolite concentrations in plasma: hexahydrocurcuminoids (○), octahydrocurcuminoids (□), curcuminoid
monoglucuronides (■), and curcuminoid monosulfates (●). (C) Time course of total curcuminoids (◊) and reduction products (▼) in brain.
(D) Time course of hexahydro- (○) and octahydrocurcuminoids (□) in brain.
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While the concentration of curcuminoids declined to
undetectable levels after 30 minutes, the reduction pro-
ducts could be detected for up to 1 h (Figure 4C). Hexa-
hydrocurcuminoids were the main reduction products in
the brain, with peak concentrations reaching approxi-
mately 40 nmol/g at five minutes after injection. The
levels of octahydrocurcuminoids were lower but per-
sisted for up to 1 h (Figure 4D).
After s.c. injection, brain curcuminoid levels were con-
siderably lower (approximately 8 nmol/g) than after i.v.
injection (Figure 5C) with a maximum attained at 30
minutes. However, levels above 1 nmol/g were observed
for more than 2 h, whereas similar concentrations were
already reached within 20 minutes after i.v. injection. In
contrast, the levels of reduction products (approximately
36 nmol/g) were comparable to those observed after i.v.
injection (approximately 46 nmol/g). Similar to i.v. injec-
tion, octahydrocurcuminoids appeared with a slight
delay compared to hexahydrocurcuminoids. Neverthe-
less, all reduction products were essentially undetectable
after 2 h following s.c. injection (Figure 5D).
This demonstrates that significant levels of curcumi-
noids can initially be achieved in plasma and brain after
both i.v. and s.c. injection. However, these levels are
transient and although the curcuminoid levels decline
somewhat more slowly after s.c injection, ultimately
they persist at detectable concentrations for no longer
than two to four hours. These results further suggest
extensive binding of injected curcuminoids to cells and
tissues, followed by rapid local metabolic conversion
and gradual release into the circulation. In addition, the
time course of the appearance of metabolites in the
brain indicates sequential reduction from hexahydrocur-
cuminoids to octahydrocurcuminoids and this aspect
was examined in further detail.
Sequential generation of curcuminoid reduction products
in brain after i.v. injection
It takes at least several minutes before brains can be
removed and cooled to the point that further metabo-
lism may be considered negligible. To investigate how
postmortem processes contribute to the metabolism of
curcuminoids, a mouse was subjected to cardiac perfu-
sion with HP-g-CD-solubilized curcuminoids diluted
with serum to a similar concentration as that achieved
by i.v injections (5%). The total amount of curcuminoids
extracted from a brain after perfusion was approxi-
mately 256 nmol/g and this may be considered the max-
imum capacity for uptake/binding within these
concentration parameters. Comparable values in other
organs were 1,383 nmol/g for the liver, 579 nmol/g for
the kidney and 287 nmol/g for the small intestine. The
primary reduction products observed in brains after per-
fusion were hexahydrocurcuminoids at a concentration
Figure 5 Concentration of curcuminoids and metabolites in
plasma (μM) and brain (nmol/g) after s.c. injection. (A-D) Same
as depicted in Figure 4, except that significant concentrations of
curcuminoid reduction products were not detected in plasma.
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of approximately 16 nmol/g and no quantifiable
amounts of octahydrocurcuminoids (Figure 6A). A simi-
lar pattern was observed in the other organs, except that
a small additional amount of glucuronidation was
detected in the liver (not shown). This suggests that
postmortem reduction is blocked at the hexahydrocur-
cuminoid stage. However, in addition to the hexahydro-
curcuminoid peaks at 280 nm wavelength, further peaks
were observed at 310 nm wavelength. The tentative
identity of these compounds was previously established
in an embryonal carcinoma cell line [36] and they are
here designated as dihydrocurcuminoidols, which may
represent alternative intermediates in the curcuminoid
reduction pathway (Figure 7)
Under in vivo conditions, the brain content of curcumi-
noids declined to essentially undetectable levels within 20
minutes after i.v. injection, concomitant with a sequential
accumulation of reduction products. Hexahydrocurcumi-
noids appeared rapidly within 2 minutes and reached a
maximum after 5 to 10 minutes. In contrast, octahydro-
curcuminoids emerged later with peak concentrations
after 10 to 15 minutes. The relative levels of hexahydro-
curcuminoids reflected those of the parental curcumi-
noids in the succession CUR > DMC > BDMC, whereas
the relative levels of octahydrocurcuminoids were
reversed. Dihydrocurcuminoidols, were also detected
here, albeit at lower relative levels (Figure 6B-F).
Differential cellular curcuminoid binding upon
solubilization in serum or HP-g-CD
Cellular curcuminoid binding as it is affected by the solu-
bilization vehicles and their dilution with mouse serum
was evaluated in cultured NT2/D1 cells, in which these
parameters have been extensively characterized [36]. Bind-
ing dose curves were generated by incubating NT2/D1
cells with increasing amounts of curcuminoids solubilized
Figure 6 Chromatograms of curcuminoids and reduction
products in brain after cardiac perfusion and i.v. injection.
Curcuminoids (right panels, retention time 22 to 28 minutes) were
monitored at wavelength 427 nm and reduction products (left panels,
retention time 6 to 12 minutes) at wavelengths 280 nm (solid lines) and
310 nm (dashed lines). The position of hexa- and
octahydrocurcuminoids are indicated by brackets. (A) Elution profiles
after cardiac perfusion. (B-F) Elution profiles at 2 minutes (B), 5 minutes
(C), 10 minutes (D), 15 minutes (E) and 20 minutes (F) after i.v. injection.
Figure 7 Structure of curcuminoids and putative alternative
reduction pathways.
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in either mouse serum or 10% HP-g-CD. The binding dose
curves yielded an apparent KD of 14.88 μM for mouse
serum- and 7.58 μM for HP-g-CD-solubilized curcumi-
noids (Figure 8A). A similar dose curve established with
curcuminoids solubilized in FCS, resulted in an apparent
KD of 9.16 μM (not shown). Nonspecific binding was
more pronounced with serum-solubilized than with HP-g-
CD-solubilized curcuminoids. Since it can be assumed
that the cellular binding affinity for curcuminoids per se
remains constant, the variations in the apparent binding
KDs may be interpreted as differences in affinities between
curcuminoids and solubilization vehicles. However, the
binding dose curves were generated with increasing
amounts of pure solubilized curcuminoids and this does
not reflect the situation in vivo, where the i.v. injected cur-
cuminoids are immediately diluted with excess blood. The
influence of serum dilution on cellular binding was, there-
fore, further examined to reflect this circumstance.
Curcuminoid preparations originally used for i.v. injec-
tions (24 mM and 6 mM HP-g-CD-solubilized, 4 mM
mouse serum-solubilized) were diluted 1:20 with
DMEM or substituted with increasing proportions of
mouse serum without curcuminoids. This resulted in
total serum concentrations ranging from 0 to 95% for
curcuminoids solubilized in HP-g-CD and 5 to 100%
for serum-solubilized curcuminoids. In all cases, cellu-
lar binding decreased with increasing serum concentra-
tions in a manner consistent with a hyperbolic decline
as described elsewhere [36] (Figure 8B). However, the
decline in binding with increasing serum concentra-
tions was dependent on the concentration of the
curcuminoids in the media. Therefore, at maximal
serum concentrations cellular binding remained at 39%
(24 mM curcuminoids), 15% (6 mM) and 12% (4 mM)
relative to the respective binding without added serum.
These results are consistent with the notion that
serum components, foremost albumin [29], act as com-
petitors for cellular binding via the affinities of their
interaction domains, which retain the curcuminoids in
solution.
Differences in cellular binding of individual curcumi-
noids were also observed, depending on whether they
were solubilized in serum (Figure 9A) or HP-g-CD
(Figure 9B). At lower curcuminoid concentrations within
the vicinity of the KD values (50% BMAX; Figure 9A, B,
left panels), the distribution of cellular curcuminoids
largely reflected the composition of the curcuminoids in
the respective media (compare Figure 1A). However,
under saturating conditions (≥ 100% BMAX; Figure 9A, B,
middle panels), which represents the curcuminoid con-
centrations employed in the serum competition experi-
ments (Figure 8B), the primary component bound to
cells incubated with curcuminoids solubilized in serum
was CUR (61%), whereas BDMC (48%) predominated in
cells incubated with curcuminoids solubilized in HP-g-
CD. Indeed, both CUR and BDMC were the main contri-
butors to nonspecific cellular binding during incubation
with the respective solubilization vehicles. During serum
competition of curcuminoids solubilized in serum, cellu-
lar binding decreased concordantly so that the relative
distribution of bound curcuminoids remained unchanged
(Figure 9A, right panel). In contrast, serum competition
of curcuminoids solubilized in HP-g-CD reduced cellular
binding of BDMC more robustly so that the relative
Figure 8 The binding of curcuminoids solubilized in mouse
serum or HP-g-CD to NT2/D1 cells. (A) Binding dose curves of
curcuminoids solubilized in either mouse serum (O) or 10%-g-CD
(■). NT2/D1 cells were incubated with increasing concentrations of
curcuminoids and the concentration of unbound (free) and the
amount of cellular bound curcuminoids was determined. From the
resulting dose curves the following binding parameters were
determined: KD: 14.87 ± 1.97 μM (O), 7.58 ± 0.92 μM (■); BMAX: 3.37
± 0.15 nmol/106 cells (O), 3.87 ± 0.15 nmol/106 cells (■). (B) Binding
dose curves with constant concentrations of curcuminoids added at
a ratio of 1:20 (5%) to media containing variable serum
concentrations (0 to 100%). Curcuminoids were solubilized in HP-g-
CD at a concentration of 24 mM (final concentration in medium: 1.2
mM; ■), diluted four-fold to 6 mM with 0.6% NaCl (final
concentration in medium: 300 μM; □), or solubilized in mouse
serum at 4 mM (final concentration in media: 200 μM; O). The data
points were fitted to a hyperbolic decay function (y = ab/(b + x)).
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distribution of bound curcuminoids was shifted toward
CUR (Figure 9B, right panel).
Overall, these results indicate that the relative affinity
of curcuminoids for HP-g-CD is weaker than for mouse
serum components, which causes a reduction in the
apparent cellular binding KD. Furthermore, the relative
affinity of BDMC for HP-g-CD is weaker than that of
CUR, which causes this component to preferentially
bind to cells at higher curcuminoid concentrations. The
preferential serum competition of cellular binding of
BDMC in media containing curcuminoids solubilized
in HP-g-CD is consistent with this idea. In general,
the differences in cellular binding characteristics
observed between curcuminoids solubilized in HP-g-CD
or serum are primarily noticed when these are used in
their pure form. Upon dilution with serum and at lower
curcuminoid concentrations, which are conditions
rapidly established in vivo, these differences become
minimized.
Discussion
The oral administration of curcumin to humans, mice
and rats has resulted in plasma levels typically not
exceeding 1 μM concentrations and similarly low tissue
levels (for recent reviews and references therein see:
[26-28,44]). Alternatively, curcumin has been delivered to
mice or rats by intraperitoneal (i.p) injection at dosages
of 6 to 100 mg/kg body weight [15,45-47]. For this pur-
pose, curcumin was either dissolved in DMSO [45-47] or
in NaOH followed by neutralization [15]. In those stu-
dies, peak curcumin plasma concentrations were within
the range of approximately 3.5 to 25 μM and brain levels
approximately 1 to 2 nmol/g. After i.v. injection in rats of
10 mg/kg curcumin solubilized in a cocktail containing
DMA/PEG/dextrose, initial plasma concentrations of
approximately 27 μM were reported [46]. Similar results
were reported in another study in which curcumin had
been solubilized in glycerol formal and i.v. injected at a
dosage of 40 mg/kg [48]. By comparison, in the present
study mice were i.v. injected with 0.1 ml of 24 mM cur-
cuminoids solubilized in 10% HP-g-CD. This represents a
total dose of 0.84 mg or approximately 33 mg/kg curcu-
minoids. Under these conditions, initial curcuminoid
plasma concentrations of about 100 μM were attainable.
Adjusted for the total dose applied, these concentrations
are similar to those observed for the rat [46], but they
resulted in transient brain concentrations of approxi-
mately 47 nmol/g (Figure 4), which were higher than
those reported in any other study. Similarly, a four-fold
higher curcuminoid dose (approximately 134 mg/kg)
administered by s.c. injection yielded maximal plasma
concentrations of approximately 23 μM and brain levels
of approximately 8 nmol/g. Although these amounts are
lower than those achieved by i.v. injection, the parental
curcuminoids were released gradually from the injection
site and they persisted longer in both plasma and brain
(Figure 5). These levels are also higher than those typi-
cally observed after i.p. injection (see above). However, in
one study curcumin was administered at a much lower
dose (3 mg/kg) and this yielded relatively high brain
levels of approximately 3.2 nmol/g at four hours after
intramuscular injection [15].
The injection protocol presented here combines the
high solubility of curcuminoids in 10% HP-g-CD with
the relatively low level of toxicity of the carrier vehicle.
In addition, HP-g-CD does not cause apparent immune
reactions that are associated with the use of heterolo-
gous serum to solubilize curcuminoids. However, at the
highest doses used for i.v. injection (33 mg/kg), toxic
reactions do develop and these may represent the
Figure 9 Distribution of curcuminoids bound to NT2/D1 cells.
(A) Distribution of mouse serum-solubilized curcuminoids bound to
NT2/D1 cells. Left panel: Chromatogram of cells incubated with
curcuminoid concentrations near the KD value (approximately 50%
BMAX) obtained from the dose curve shown in Figure 8A (O). Middle
panel: Chromatogram of cells incubated at saturating curcuminoid
concentrations (≥ BMAX, 200 μM curcuminoids added to medium at
a total of 5% serum). Right panel: Same as middle panel except that
cells were incubated with 100% serum. The middle and right panels
illustrate the starting and end points of the serum competition
curve shown in Figure 8B (O). The relative contribution of each
curcuminoid is indicated as a percentage of the total. (B)
Distribution of HP-g-CD-solubilized curcuminoids bound to NT2/D1
cells. Left panel: Chromatogram of cells incubated with curcuminoid
concentrations near the KD value (approximately 50% BMAX)
obtained from the dose curve shown in Figure 8A (■). Middle panel:
Chromatogram of cells incubated at saturating curcuminoid
concentrations (≥ BMAX, 300 μM curcuminoids added to medium
without serum). Right panel: Same as middle panel except that cells
were incubated with 95% serum. The middle and right panels
illustrate the starting and end points of the serum competition
curve shown in Figure 8B (□).
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maximum amount of curcuminoids tolerated before
lethal effects occur. After a single i.v. injection, high
plasma levels are exceedingly transient and the concen-
tration of native curcuminoids drops to insignificant
levels within 20 minutes (Figure 4). The decline in the
level of circulating curcuminoids can be considered due
to rapid metabolism combined with widespread binding/
uptake to cells and tissues.
The binding of curcuminoids to cells in culture has
been described in detail elsewhere [36]. Those studies
were expanded to include preparations employed here,
where curcuminoids had been sequentially solubilized in
mouse serum and 10% HP-g-CD (Figure 8). This was
done by first adding curcuminoids as a solid powder fol-
lowed by the addition of DMSO-dissolved curcuminoids.
This method results in a maximal solubility of curcumi-
noids and a relatively balanced composition [29]. The
apparent binding KDs in these preparations were higher
for curcuminoids solubilized in mouse serum (14.88
μM) than in FCS (9.16 μM). Since mouse serum has the
capacity to solubilize higher concentrations of curcumi-
noids than FCS (3 to 4 mM vs. approximately 1.7 mM
[29]), it is likely that these differences in binding KDs
reflect differences in affinities or concentrations between
the curcuminoid interaction domains in serum compo-
nents, as it may be reasonably assumed that the cellular
binding affinities remain constant. It is further expected
that curcuminoids solubilized in sera from different spe-
cies or possibly different preparations from the same
species, will produce different apparent cellular binding
KDs due to their variable serum compositions. In addi-
tion, alternative solubilization vehicles may have differ-
ential affinities for individual curcuminoids. This is
exemplified by the cellular binding of individual curcu-
minoids solubilized in HP-g-CD (Figure 9). Although
curcuminoids solubilized in either HP-g-CD or serum
have similar compositions (Figure 1), the primary curcu-
minoids bound to cells at saturating concentrations
were BDMC and CUR, respectively. However, upon
dilution with excess serum, both preparations converged
to the same compositions of cellular-bound curcumi-
noids (Figure 9). Although these observations were
made with cultured cells, it is likely that similar binding
occurs in vivo. Indeed, the extensive binding of curcu-
minoids to brain (Figure 6) and other organs (not
shown) shows a similar distribution pattern as that
obtained with cultured cells incubated with curcumi-
noids and excess serum. Except for considerations relat-
ing to solubilization capacity, toxicity or immune
reactions, it is in this case irrelevant whether curcumi-
noids are solubilized in serum or HP-g-CD.
The metabolic conversion of curcuminoids after i.v.
injection is rapid and it includes both conjugation and
reduction products (Figure 4). Since conjugation takes
place in the liver, intestines and kidneys, the resulting
products are observed primarily in plasma but also at the
sites of excretion [48-51]. In addition to conjugation pro-
ducts, the hexa- and octahydrocurcuminoid reduction
products are also prominently represented in the circula-
tion. It is likely that these are primarily contributed by
curcuminoids that were taken up by peripheral cells and
tissues, metabolized locally, and subsequently released
into the bloodstream. In contrast, after s.c. injection the
curcuminoid reduction products are not readily detected
in plasma. This is most likely due to the more gradual
release from tissues followed by rapid excretion.
Although only the monoconjugates of sulfate and glucur-
onide were investigated here, it is likely that mixed dicon-
jugates are also produced [48,50,51]. Some studies have
reported the formation of tetrahydrocurcumin in mice
[47,49], which was not detected in this study. Instead, the
hexa- and octahydrocurcuminoids predominated. In
addition, different reduction products with different phy-
sical characteristics, here referred to as dihydrocurcumi-
noidols, were detected in the brain. These compounds
were first identified as the final reduction products in the
teratocarcinoma cell line NT2/D1 [36], while its presence
in vivo has not been previously reported. However, dihy-
drocurcuminoidols are most prominently produced after
perfusion under post-mortem conditions. Their time-
dependent production in the brain following i.v. injection
also seems to be correlated with the amount of unmodi-
fied curcuminoids present. It can, therefore, not be
excluded that this is a post-mortem effect that rapidly
occurs during the removal of tissues. The enzyme
systems responsible for the reductive conversion of cur-
cuminoids have not yet been conclusively identified.
However, it appears that octahydrocurcuminoids are
sequentially generated from hexahydrocurcuminoids. For
example, during perfusion only hexahydrocurcuminoids
together with smaller amounts of dihydrocurcuminoidols
were generated and since the post-mortem conversion to
octahydrocurcuminoids was blocked, there was a larger
relative accumulation of hexahydro-BDMC compared to
in vivo conditions (Figure 6). This indicates that the over-
all conversion to octahydrocurcuminoids requires dis-
tinct enzyme systems with different substrate specificities
and metabolic requirements. The more efficient genera-
tion of octahydro-BDMC than octahydro-CUR is consis-
tent with this notion, as is the gender-specific generation
of reduction products in the rat [39]. The curcumin redu-
cing enzymes have also been found to be distributed
between cytoplasmic and microsomal compartments
[38]. In addition, different cell lines in culture produce
different reduction products. For example, in the astrocy-
toma cell line CCF-STTG1, reduction proceeds to the
octahydrocurcuminoid stage, whereas in HeLa cells hexa-
hydrocurcuminoids are the end products [36]. These cell
Quitschke et al. Alzheimer’s Research & Therapy 2013, 5:16
http://alzres.com/content/5/2/16
Page 13 of 15
lines also produce varying amounts of dihydrocurcumi-
noidols [36]. Based on these observations, possible alter-
native reduction pathways for curcuminoid reduction are
proposed (Figure 7).
Conclusions
This study was undertaken to examine the feasibility of
using an injectable form of curcuminoids to modulate
the formation of amyloid plaques in brains of Alzheimer
transgenic mice. This was based on the premise that
relatively low concentrations of curcumin suffice to
eliminate or reverse amyloid fibril formation in vitro.
Furthermore, a number of studies have reported a
reduction in plaque load following long-term (four to
nine months) oral uptake of curcumin in similar trans-
genic mouse models. Despite low plasma levels, the
plaque load was reduced to 48 to 69% of control values
[9,15-17]. However, including curcumin in the diet
represents chronic exposure to low levels of curcumin.
In this study, the amount of curcuminoids injected was
relatively high, yielding a significant rapid distribution
into both plasma and tissues. Nevertheless, the high rate
of metabolism rendered these levels short-lived. In
effect, the long-term intermittent exposure at intervals
of once/week had no discernable influence on plaque
formation, although at four-fold higher dosage and with
a frequency of twice/week for one month, a reduction in
plaque load to about 70% of control values was
observed. Indeed, similar plaque load reductions were
reported in the same strain of mice after daily tail vein
injections for seven days using only 7.5 mg/kg curcumin
[8]. It is, therefore, conceivable that inhibition of plaque
formation and plaque resolution depends on a more fre-
quent administration of curcuminoids. Since frequent
long-term tail vein injections in mice are problematic,
these could be augmented or substituted with better tol-
erated subcutaneous injections in future studies. These
modes of administration could also be complemented
with formulations for improved oral uptake. For exam-
ple, preliminary studies with HP-g-CD-solubilized curcu-
minoids in drinking water yielded consistent plasma
concentrations in the range of 0.5 to 1 μM (not shown).
Therefore, combining the oral uptake of curcuminoids
via both food and drinking water with injection proto-
cols may result in more effective procedures for plaque
prevention and elimination.
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